pSivida Corp. (NASDAQ:PSDV) has been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.20.

A number of analysts recently commented on PSDV shares. ValuEngine lowered pSivida from a “sell” rating to a “strong sell” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of pSivida in a report on Wednesday, November 8th. Finally, Laidlaw started coverage on pSivida in a report on Wednesday, November 8th. They set a “buy” rating and a $5.00 price target on the stock.

pSivida (NASDAQ:PSDV) opened at $1.28 on Friday. pSivida has a 1 year low of $1.03 and a 1 year high of $2.45.

pSivida (NASDAQ:PSDV) last announced its earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.15). The company had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $0.74 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%. equities analysts forecast that pSivida will post -0.58 EPS for the current year.

A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new position in shares of pSivida Corp. (NASDAQ:PSDV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida at the end of the most recent quarter. 9.70% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “pSivida Corp. (PSDV) Receives Average Rating of “Buy” from Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/03/psivida-corp-psdv-receives-average-rating-of-buy-from-analysts.html.

About pSivida

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Analyst Recommendations for pSivida (NASDAQ:PSDV)

Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.